The Effect of Corticotropin-Releasing Hormone (CRH) on the Adrenal Medulla in Hypophysectomized Rats
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Expression Pattern of Delta-Like 1 Homolog in Developing Sympathetic Neurons and Chromaffin Cells
Published in "Gene Expression Patterns 30: 49–54, 2018" which should be cited to refer to this work. Expression pattern of delta-like 1 homolog in developing sympathetic neurons and chromaffin cells ∗ Tehani El Faitwria,b, Katrin Hubera,c, a Institute of Anatomy & Cell Biology, Albert-Ludwigs-University Freiburg, Albert-Str. 17, 79104, Freiburg, Germany b Department of Histology and Anatomy, Faculty of Medicine, Benghazi University, Benghazi, Libya c Department of Medicine, University of Fribourg, Route Albert-Gockel 1, 1700, Fribourg, Switzerland ABSTRACT Keywords: Delta-like 1 homolog (DLK1) is a member of the epidermal growth factor (EGF)-like family and an atypical notch Sympathetic neurons ligand that is widely expressed during early mammalian development with putative functions in the regulation Chromaffin cells of cell differentiation and proliferation. During later stages of development, DLK1 is downregulated and becomes DLK1 increasingly restricted to specific cell types, including several types of endocrine cells. DLK1 has been linked to Adrenal gland various tumors and associated with tumor stem cell features. Sympathoadrenal precursors are neural crest de- Organ of Zuckerkandl rived cells that give rise to either sympathetic neurons of the autonomic nervous system or the endocrine Development ffi Neural crest chroma n cells located in the adrenal medulla or extraadrenal positions. As these cells are the putative cellular Phox2B origin of neuroblastoma, one of the most common malignant tumors in early childhood, their molecular char- acterization is of high clinical importance. In this study we have examined the precise spatiotemporal expression of DLK1 in developing sympathoadrenal cells. We show that DLK1 mRNA is highly expressed in early sympa- thetic neuron progenitors and that its expression depends on the presence of Phox2B. -
Oxytocin Is an Anabolic Bone Hormone
Oxytocin is an anabolic bone hormone Roberto Tammaa,1, Graziana Colaiannia,1, Ling-ling Zhub, Adriana DiBenedettoa, Giovanni Grecoa, Gabriella Montemurroa, Nicola Patanoa, Maurizio Strippolia, Rosaria Vergaria, Lucia Mancinia, Silvia Coluccia, Maria Granoa, Roberta Faccioa, Xuan Liub, Jianhua Lib, Sabah Usmanib, Marilyn Bacharc, Itai Babc, Katsuhiko Nishimorid, Larry J. Younge, Christoph Buettnerb, Jameel Iqbalb, Li Sunb, Mone Zaidib,2, and Alberta Zallonea,2 aDepartment of Human Anatomy and Histology, University of Bari, 70124 Bari, Italy; bThe Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029; cBone Laboratory, The Hebrew University of Jerusalem, Jerusalem 91120, Israel; dGraduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, Miyagi 981-8555 Japan; and eCenter for Behavioral Neuroscience, Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30322 Communicated by Maria Iandolo New, Mount Sinai School of Medicine, New York, NY, February 19, 2009 (received for review October 24, 2008) We report that oxytocin (OT), a primitive neurohypophyseal hor- null mice (5). But the mice are not rendered diabetic, and serum mone, hitherto thought solely to modulate lactation and social glucose homeostasis remains unaltered (9). Thus, whereas the bonding, is a direct regulator of bone mass. Deletion of OT or the effects of OT on lactation and parturition are hormonal, actions OT receptor (Oxtr) in male or female mice causes osteoporosis that mediate appetite and social bonding are exerted centrally. resulting from reduced bone formation. Consistent with low bone The precise neural networks underlying OT’s central effects formation, OT stimulates the differentiation of osteoblasts to a remain unclear; nonetheless, one component of this network mineralizing phenotype by causing the up-regulation of BMP-2, might be the interactions between leptin- and OT-ergic neurones which in turn controls Schnurri-2 and 3, Osterix, and ATF-4 expres- in the hypothalamus (10). -
Novel Autocrine Feedback Control of Catecholamine Release a Discrete Chromogranin a Fragment Is a Noncompetitive Nicotinic Cholinergic Antagonist Sushil K
Novel Autocrine Feedback Control of Catecholamine Release A Discrete Chromogranin A Fragment is a Noncompetitive Nicotinic Cholinergic Antagonist Sushil K. Mahata,* Daniel T. O’Connor,* Manjula Mahata,* Seung Hyun Yoo,‡ Laurent Taupenot,* Hongjiang Wu,* Bruce M. Gill,* and Robert J. Parmer* *Department of Medicine and Center for Molecular Genetics, University of California, San Diego, California 92093 and Department of Veterans Affairs Medical Center, San Diego, California 92161, and ‡National Institute of Deafness and Communicative Disorders, National Institutes of Health, Bethesda, Maryland 20892 Abstract completely established, recent evidence implicates chromogra- nin A as a precursor of several small biologically active secre- Catecholamine secretory vesicle core proteins (chromog- tion-inhibitory peptides that may play an autocrine regulatory ranins) contain an activity that inhibits catecholamine re- role in neuroendocrine secretion from a variety of cell types (3, lease, but the identity of the responsible peptide has been 7–10). The primary structure of chromogranin A reveals 8–10 elusive. Size-fractionated chromogranins antagonized nico- conserved pairs of basic amino acids that represent potential tinic cholinergic-stimulated catecholamine secretion; the in- proteolytic cleavage sites for the generation of such peptides hibitor was enriched in processed chromogranin fragments, (11–17), and chromogranin A is a substrate for the prohor- and was liberated from purified chromogranin A. Of 15 syn- mone convertases (18–20). of chromogranin A, one To date, several chromogranin A–derived peptides have %80 ف thetic peptides spanning (bovine chromogranin A344–364 [RSMRLSFRARGYGFRG- been identified that affect the secretory function of the parent PGLQL], or catestatin) was a potent, dose-dependent (IC50 cells. -
Searching for Novel Peptide Hormones in the Human Genome Olivier Mirabeau
Searching for novel peptide hormones in the human genome Olivier Mirabeau To cite this version: Olivier Mirabeau. Searching for novel peptide hormones in the human genome. Life Sciences [q-bio]. Université Montpellier II - Sciences et Techniques du Languedoc, 2008. English. tel-00340710 HAL Id: tel-00340710 https://tel.archives-ouvertes.fr/tel-00340710 Submitted on 21 Nov 2008 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE MONTPELLIER II SCIENCES ET TECHNIQUES DU LANGUEDOC THESE pour obtenir le grade de DOCTEUR DE L'UNIVERSITE MONTPELLIER II Discipline : Biologie Informatique Ecole Doctorale : Sciences chimiques et biologiques pour la santé Formation doctorale : Biologie-Santé Recherche de nouvelles hormones peptidiques codées par le génome humain par Olivier Mirabeau présentée et soutenue publiquement le 30 janvier 2008 JURY M. Hubert Vaudry Rapporteur M. Jean-Philippe Vert Rapporteur Mme Nadia Rosenthal Examinatrice M. Jean Martinez Président M. Olivier Gascuel Directeur M. Cornelius Gross Examinateur Résumé Résumé Cette thèse porte sur la découverte de gènes humains non caractérisés codant pour des précurseurs à hormones peptidiques. Les hormones peptidiques (PH) ont un rôle important dans la plupart des processus physiologiques du corps humain. -
Neuroendocrinology 165P PC125 EFFECT of CALCITONIN GENE
Poster Communication - Neuroendocrinology 165P PC125 PC127 EFFECT OF CALCITONIN GENE-RELATED PEPTIDE ON Effects of the potent hop-derived phytoestrogen, GnRH mRNA EXPRESSION IN THE GT1-7 CELL 8-prenylnaringenin, on the reproductive neuroendocrine axis 1 1 1 2 1 J. Kinsey-Jones ,X.Li ,J.Bowe ,S.Brain and K. O’Byrne J. Bowe1,J.Kinsey-Jones1,X.Li1,S.Brain2 and K. O’Byrne1 1Division of Reproductive Health, Endocrinology and Development, 1Division of Reproductive Health, Endocrinology and Development, Kings College London, London, UK and 2Centre for Cardiovascular King’s College London, London, UK and 2Centre for Cardiovascular Biology, Kings College London, London, UK Biology, King’s College London, London, UK Calcitonin gene-related peptide (CGRP) has recently been The phytoestrogen, 8-prenylnaringenin (8-PN), is the most potent shown to induce a profound suppression of the hypothala- phytoestrogen discovered to date. Derived from hops, it is pres- mic gonadotrophin-releasing hormone (GnRH) pulse gen- ent in dietary supplements currently marketed for natural breast erator, resulting in an inhibition of pulsatile luteinising hor- enhancement, though little is known about efficacy rates or other mone (LH) secretion in the rat (Li et al., 2004). The aims of effects (Coldham & Sauer, 2001). 8-PN is also of potential inter- the present study were, (i) to determine the presence of the est in the treatment of menopausal symptoms and diseases involv- CGRP receptor subunits, receptor activity modifying protein- ing angiogenesis. It is known that various phytoestrogens pro- 1(RAMP-1) and calcitonin receptor like receptor (CL), both duce inhibitory effects on gonadotrophin secretion in both of which are required for functional activity, in the GT1-7 humans and animals (McGarvey et al, 2001). -
Injection Safely and Effectively
HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- These highlights do not include all the information needed to use MIACALCIN injection safely and effectively. See full prescribing Injection: 200 International Units per mL sterile solution in 2 mL multi- information for MIACALCIN injection. dose vials (3) MIACALCIN® (calcitonin-salmon) injection, synthetic, for subcutaneous ----------------------------CONTRAINDICATIONS------------------------------ or intramuscular use Hypersensitivity to calcitonin-salmon or any of the excipients (4) Initial U.S. Approval: 1975 -----------------------WARNINGS AND PRECAUTIONS------------------------ -------------------------------RECENT MAJOR CHANGES----------------------- Serious hypersensitivity reactions, including reports of fatal anaphylaxis Indications and Usage (1.4) 03/2014 have been reported. Consider skin testing prior to treatment in patients with Warnings and Precautions (5.3) 03/2014 suspected hypersensitivity to calcitonin-salmon (5.1) ----------------------------INDICATIONS AND USAGE--------------------------- Hypocalcemia has been reported. Ensure adequate intake of calcium and vitamin D (5.2) Miacalcin synthetic injection is a calcitonin, indicated for the following Malignancy: A meta-analysis of 21 clinical trials suggests an increased risk conditions: of overall malignancies in calcitonin-salmon-treated patients (5.3, 6.1) Treatment of symptomatic Paget’s disease of bone when alternative Circulating antibodies to calcitonin-salmon -
Effects of Β-Lipotropin and Β-Lipotropin-Derived Peptides on Aldosterone Production in the Rat Adrenal Gland
Effects of β-Lipotropin and β-Lipotropin-derived Peptides on Aldosterone Production in the Rat Adrenal Gland Hiroaki Matsuoka, … , Patrick J. Mulrow, Roberto Franco-Saenz J Clin Invest. 1981;68(3):752-759. https://doi.org/10.1172/JCI110311. Research Article To investigate the role of non-ACTH pituitary peptides on steroidogenesis, we studied the effects of synthetic β-lipotropin, β-melanotropin, and β-endorphin on aldosterone and corticosterone stimulation using rat adrenal collagenase-dispersed capsular and decapsular cells. β-lipotropin induced a significant aldosterone stimulation in a dose-dependent fashion (10 nM-1 μM). β-endorphin, which is the carboxyterminal fragment of β-lipotropin, did not stimulate aldosterone production at the doses used (3 nM-6 μM). β-melanotropin, which is the middle fragment of β-lipotropin, showed comparable effects on aldosterone stimulation. β-lipotropin and β-melanotropin did not affect corticosterone production in decapsular cells. Although ACTH1-24 caused a significant increase in cyclic AMP production in capsular cells in a dose-dependent fashion (1 nM-1 μM), β-lipotropin and β-melanotropin did not induce an increase in cyclic AMP production at the doses used (1 nM-1 μM). The β-melanotropin analogue (glycine[Gly]10-β-melanotropin) inhibited aldosterone production induced by β- lipotropin or β-melanotropin, but did not inhibit aldosterone production induced by ACTH1-24 or angiotensin II. Corticotropin-inhibiting peptide (ACTH7-38) inhibited not only ACTH1-24 action but also β-lipotropin or β-melanotropin action; however it did not affect angiotensin II-induced aldosterone production. (saralasin [Sar]1; alanine [Ala]8)- Angiotensin II inhibited the actions of β-lipotropin and β-melanotropin as well as angiotensin II. -
Lipotropin, Melanotropin and Endorphin: in Vivo Catabolism and Entry Into Cerebrospinal Fluid
LE JOURNAL CANAD1EN DES SCIENCES NEUROLOGIQUES Lipotropin, Melanotropin and Endorphin: In Vivo Catabolism and Entry into Cerebrospinal Fluid P. D. PEZALLA, M. LIS, N. G. SEIDAH AND M. CHRETIEN SUMMARY: Anesthetized rabbits were INTRODUCTION (Rudman et al., 1974). These findings given intravenous injections of either Beta-lipotropin (beta-LPH) is a suggest, albeit weakly, that the pep beta-lipotropin (beta-LPH), beta- peptide of 91 amino acids that was tide might cross the blood-brain bar melanotropin (beta-MSH) or beta- first isolated from ovine pituitary rier. In the case of beta-endorphin, endorphin. The postinjection concentra glands (Li et al., 1965). Although there are physiological studies both tions of these peptides in plasma and cerebrospinal fluid (CSF) were measured beta-LPH has a number of physiologi supporting and negating the possibil by radioimmunoassay (RIA). The plasma cal actions including the stimulation ity that beta-endorphin crosses the disappearance half-times were 13.7 min of lipolysis and melanophore disper blood-brain barrier. The study of for beta-LPH, 5.1 min for beta-MSH, and sion, it is believed to function princi Tseng et al. (1976) supports this pos 4.8 min for beta-endorphin. Circulating pally as a prohormone for beta- sibility since they observed analgesia beta-LPH is cleaved to peptides tenta melanotropin (beta-MSH) and beta- in mice following intravenous injec tively identified as gamma-LPH and endorphin. Beta-MSH, which com tion of beta-endorphin. However, beta-endorphin. Each of these peptides prises the sequence 41-58 of beta- Pert et al. (1976) were unable to elicit appeared in the CSF within 2 min postin LPH, is considerably more potent central effects in rats by intravenous jection. -
(Calcitonin-Salmon) Nasal Spray, for Intranasal Use Vitamin D (5.2) Initial U.S
HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------- WARNINGS AND PRECAUTIONS ---------------------- These highlights do not include all the information needed to use • Serious hypersensitivity reactions including anaphylactic shock have been MIACALCIN nasal spray safely and effectively. See full prescribing reported. Consider skin testing prior to treatment in patients with information for MIACALCIN nasal spray. suspected hypersensitivity to calcitonin-salmon (5.1) • Hypocalcemia has been reported. Ensure adequate intake of calcium and MIACALCIN® (calcitonin-salmon) nasal spray, for intranasal use vitamin D (5.2) Initial U.S. Approval: 1975 • Nasal adverse reactions, including severe ulceration can occur. Periodic nasal examinations are recommended (5.3) • Malignancy: A meta-analysis of 21 clinical trials suggests an increased ------------------------------ INDICATIONS AND USAGE --------------------------- risk of overall malignancies in calcitonin-salmon-treated patients (5.4, Miacalcin nasal spray is a calcitonin, indicated for the treatment of 6.1) postmenopausal osteoporosis in women greater than 5 years postmenopause • Circulating antibodies to calcitonin-salmon may develop, and may cause when alternative treatments are not suitable. Fracture reduction efficacy has not loss of response to treatment (5.5) been demonstrated (1.1) ------------------------------- ADVERSE REACTIONS ------------------------------- Limitations of Use: Most common adverse reactions (3% or greater) are rhinitis, epistaxis and other • Due to the possible association between malignancy and calcitonin nasal symptoms, back pain, arthralgia, and headache (6) salmon use, the need for continued therapy should be re-evaluated on a periodic basis (1.2, 5.4) To report SUSPECTED ADVERSE REACTIONS, contact Mylan • Miacalcin nasal spray has not been shown to increase bone mineral Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1 density in early postmenopausal women (1.2) 800-FDA-1088 or www.fda.gov/medwatch. -
I AMYLIN MEDIATES BRAINSTEM
AMYLIN MEDIATES BRAINSTEM CONTROL OF HEART RATE IN THE DIVING REFLEX A Dissertation Submitted to The Temple University Graduate Board In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy By Fan Yang May, 2012 Examination committee members: Dr. Nae J Dun (advisor), Dept. of Pharmacology, Temple University Dr. Alan Cowan, Dept. of Pharmacology, Temple University Dr. Lee-Yuan Liu-Chen, Dept. of Pharmacology, Temple University Dr. Gabriela Cristina Brailoiu, Dept. of Pharmacology, Temple University Dr. Parkson Lee-Gau Chong, Dept. of Biochemistry, Temple University Dr. Hreday Sapru (external examiner), Depts. of Neurosciences, Neurosurgery & Pharmacology/Physiology, UMDNJ-NJMS. i © 2012 By Fan Yang All Rights Reserved ii ABSTRACT AMYLIN’S ROLE AS A NEUROPEPTIDE IN THE BRAINSTEM Fan Yang Doctor of Philosophy Temple University, 2012 Doctoral Advisory Committee Chair: Nae J Dun, Ph.D. Amylin, or islet amyloid polypeptide is a 37-amino acid member of the calcitonin peptide family. Amylin role in the brainstem and its function in regulating heart rates is unknown. The diving reflex is a powerful autonomic reflex, however no neuropeptides have been described to modulate its function. In this thesis study, amylin expression in the brainstem involving pathways between the trigeminal ganglion and the nucleus ambiguus was visualized and characterized using immunohistochemistry. Its functional role in slowing heart rate and also its involvement in the diving reflex were elucidated using stereotaxic microinjection, whole-cel patch-clamp, and a rat diving model. Immunohistochemical and tract tracing studies in rats revealed amylin expression in trigeminal ganglion cells, which also contained vesicular glutamate transporter 2 positive. -
Extra-Adrenal Chromaffin Cells of the Zuckerkandl´S Paraganglion: Morphological and Electrophysiological Study
275 Extra-adrenal chromaffin cells of the Zuckerkandl´s paraganglion: morphological and electrophysiological study. Beatriz Galán-Rodríguez, M. Pilar Ramírez-Ponce, Fadwa El Banoua, Juan A. Flores, Juan Bellido and Emilio Fernández-Espejo. Departamento de Fisiología Médica y Biofísica. Universidad de Sevilla. Spain. Correspondence: Dra. Beatriz Galán Rodríguez or Dr. Emilio Fernández-Espejo, Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, 41009. Sevilla. Spain. Phone: 34-954-556584; Fax: 34-954-551769; Email: [email protected] ; [email protected] Cell Biology of the Chromaffin Cell R. Borges & L. Gandía Eds. Instituto Teófilo Hernando, Spain, 2004 Cell Biology of the Chromaffin Cell 276 Parkinson´s disease is one of the most important neurodegenerative disorders that affects to one out of a hundred of the world population elder than 65. It has been observed in our laboratory, for the first time, that intrabrain transplantation of chromaffin cell aggregates from the Zuckerkandl´s organ, an extraadrenal paraganglion located adjacent to the lower abdominal aorta, induced gradual improvement of functional deficits in animal models of Parkinson´s disease1. This functional regeneration was likely caused by long-survival of grafted cells and chronic trophic action of dopaminotrophic factors, glial cell line-derived 2,3 4,5 factor (GDNF) and transforming growth factor beta1 (TGF-b1) , which are expressed and delivered by long-surviving grafted chromaffin cells. The objective of this study is to discern the morphological and cytological characteristics of extra-adrenal cells of the Zuckerkandl’s organ. On the other hand, long survival of extra-adrenal chromaffin cells could be related to resistance to hypoxia, since it is certainly know that hypoxia is a primary factor involved in cell death after intrabrain grafting. -
A 0.70% E 0.80% Is 0.90%
US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.